Navigation Links
Virginia Tech helping to develop higher quality, disease-resistant wheat varieties

Researchers at Virginia Tech's College of Agriculture and Life Sciences are part of consortium of public wheat breeders and scientists that have been awarded $5 million from the USDA to enable routine use of modern breeding technologies to produce higher quality, disease-resistant wheat.

"For the past two decades, an intensive amount of molecular research has been conducted wherein chromosome specific DNA sequences or markers have been used to identify genes controlling traits of economic importance in wheat varieties. This integrated project will enable us to demonstrate that DNA markers associated with such traits can be used on a routine basis to develop superior wheat varieties," said Carl Griffey, professor of crop and soil environmental sciences at Virginia Tech and consortium project coordinator for the Mid-Atlantic region. "These technologies will accelerate development of U.S. varieties that are durable to plant diseases, more productive, and of better end use quality, which are all essential for increasing competitiveness of U.S. wheat in global markets."

Griffey, along with other researchers from Virginia, Kentucky, Maryland, and North Carolina, will be specifically looking at wheat traits of critical importance in the Mid-Atlantic region where diseases such as powdery mildew, leaf rust, stripe rust, and fusarium head blight result in significant losses in yield and quality each year. For example, researchers will be identifying and using DNA markers to select varieties possessing genes conferring durable resistant to powdery mildew, which causes annual crop loss of 10 to 30 percent in the Mid-Atlantic region. Researchers also will be identifying genes that confer superior milling and baking qualities.

The new technology implemented in this project is called Marker Assisted Selection (MAS). MAS involves the direct use of molecular markers that are located in the same chromosome region as the trait of interest to select for genes c
'"/>

Source:Virginia Tech


Page: 1 2

Related biology news :

1. Virginia Tech group adds tools to DNA-targeted anti-cancer drugs
2. Virginia Tech, Nanjing Institute researchers discover half-billion year-old fossils
3. Virginia Tech football player uses prototype cast
4. Virginia Tech scientists develop process for creating biocompatible fibers
5. Virginia Bioinformatics Institutes launches microbial database
6. Virginia Techs System X supercomputer provides super tool for simulation of cell division
7. How marine reserves are giving coral reefs a helping hand
8. NASA technology helping injured US troops
9. Cornell researcher helping develop quick, cheap HIV/AIDS test
10. A much-needed shot in the arm for HIV vaccine development
11. Clam embryo study shows pollutant mixture adversely affects nerve cell development
Post Your Comments:
(Date:5/21/2015)... , May 21, 2015 ... Imaging Market by Solutions (Hardware, Software, Services), by Applications ... & others), by End-Users (Military & Defense & ... MarketsandMarkets, Thermal Imaging Market is expected to grow ... by 2020, at a Compound Annual Growth Rate ...
(Date:5/20/2015)... May 20, 2015 NXT-ID, Inc. (NASDAQ: ... wholly owned subsidiary, 3D-ID LLC, a company engaged in ... for the biometrics technology portion of the recently awarded ... the Department of the Army. 3D-ID LLC ... for government, law enforcement and security agencies. ...
(Date:5/19/2015)... DUBLIN , May 19, 2015 /PRNewswire/ ... ) has announced the addition of the  ... their offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A ... provides an in-depth analysis of the current ... introduction of gene-based tests, their working principles ...
Breaking Biology News(10 mins):Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3Global Genetic Testing Market Outlook 2018 2
... study in the September 6 issue of the Journal of ... an important ciliary protein, CEP290. The results could be applied ... Mutations in human CEP290 cause cilia-related disorders that range in ... known to cause Meckel syndrome, Joubert syndrome, and NPHPthe most ...
... bacterial cells that act in their own interests ... can actually reduce the severity of infection. ... could be exploited to treat antibiotic-resistant infections, according ... General Microbiology,s autumn meeting today. Bacteria work ...
... Society is delighted to announce its 2011 Society Fellows. ... in science, contributions to the expansion of the field ... Fellows will be honored at the Awards Ceremony during ... 7, 2011 at the Baltimore Convention Center in Baltimore, ...
Cached Biology News:Backstabbing bacteria: A new treatment for infection? 2
(Date:6/2/2015)... 2015 TapImmune, Inc. (OTCQB: TPIV), a clinical ... reached an agreement whereby the institutional investors will have ... provide the Company up to $4.93M in near term ... statement. Under the restructured terms and subject to certain ... which could result in a larger influx of capital ...
(Date:6/2/2015)... , June 02, 2015 Research and ... the "Bioburden Testing Market by Product , Test, ... report to their offering. The bioburden testing ... from $354.4 Million in 2014, growing at a CAGR ... basis of products, the microbial limit testing market is ...
(Date:6/2/2015)... , June 2, 2015 Meet ... Emotion Scanner. Scan & Read People. Analyze emotions and ... ART Concepts, including the very first Responsive-RPG: "The Eye: ... , , , , ... and truly affect your inner feelings - and those ...
(Date:6/2/2015)... June 2, 2015   Y-Prime, Inc ., ... BIO Exhibition 2015 in Philadelphia ... largest biotechnology gathering, allows influential decision makers from ... they can evaluate emerging technologies such as YPrime. ... in the design, implementation and management of Interactive ...
Breaking Biology Technology:TapImmune Announces Agreement To Facilitate Near Term Capital Infusion; Expediting Path Toward Phase II Trial Initiation 2TapImmune Announces Agreement To Facilitate Near Term Capital Infusion; Expediting Path Toward Phase II Trial Initiation 3Bioburden Testing Market 2015 - Global Forecasts to 2019 2ARGUS - The World's First Inner Emotion Scanner Launches on KickStarter 2ARGUS - The World's First Inner Emotion Scanner Launches on KickStarter 3YPrime at BIO Exhibition in Philadelphia and DIA in Washington DC during the month of June 2
... The secret of a successful sandcastle could aid the revival ... by Durham University. Researchers, led by experts at Durham,s ... strength of rammed earth, which is growing in popularity as ... a little water to stand up, the Durham engineers found ...
... 2 Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR ... Phase 3 clinical study of fidaxomicin in patients with ... by clinical investigator, Mark A. Miller, M.D., at the ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO ) , , ...
... 2 Document sharing inefficiencies in clinical trials cost investigative ... recent online poll by IntraLinks(R), the leading provider of critical ... document-related administrative duties and repetitive requests for information as significant ... of the polling results include: , , ...
Cached Biology Technology:Secret of sandcastle construction could help revive ancient building technique, researchers say 2Secret of sandcastle construction could help revive ancient building technique, researchers say 3Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI 2Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI 3Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI 4Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI 5Document Management Inefficiencies Cost Clinical Study Sites Time, Money 2
ABgene® supplies a 94kDa ultra-pure recombinant thermostable DNA polymerase obtained by high level expression of the Taq DNA polymerase gene in E. coli....
... This system uses the Adept CE 4100 ... Ultra-Fast Scanning UV/Visible detector for added flexibility and ... a trustworthy alternative to a photodiode array detection ... one detector is required for method development and ...
... number is a new product number, ... number. If showing no availability yet, ... number (E6152) or contact customer service ... diam. 11.25 6.40 in. ...
... Analysis of large numbers of samples may be ... requires minimum operator attention. System control and ... interface CE 4900. The elegant, powerful and ... XP and Windows 98 and 2000., The supplied ...
Biology Products: